Advertisement
Home »

Ruxolitinib Cream: A Chance for Treatment Success for Patients With Mild Hidradenitis Suppurativa

Apr 01, 2024

REFERENCES & ADDITIONAL READING

Porter M, et al. Efficacy and safety of ruxolitinib cream in patients with hidradenitis suppurativa (Hurley Stage I and II): results from a randomized, double-blind, vehicle-controlled phase 2 study. Presented at: AAD 2024 Annual Meeting, March 8-12, 2024, San Diego, CA, USA.

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement